TELA Bio, Inc. (TELA)
Nasdaq · Healthcare · Medical Devices
$1.140.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $51.5M
- 52-week range
- $0.501 – $1.60
- 52-week change
- −27.39%
- EPS (trailing)
- −$0.77
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $80.3M (+15.84%)
- Net income
- −$38.8M
- Operating margin
- −42.0%
- Diluted EPS
- −$0.83
- Free cash flow
- −$28.7M
From the company’s annual report on SEC EDGAR.
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Headquarters: Malvern, United States · 218 employees · telabio.com